Notice: Trading of InMed Pharmaceuticals halted at 09:47 AM EST due to "LULD pause". InMed Pharmaceuticals (INM) Competitors $5.05 +0.10 (+2.02%) Closing price 04:00 PM EasternExtended Trading$4.18 -0.87 (-17.23%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends INM vs. CSCI, RLMD, CLDI, TXMD, ACXP, APLM, CLRB, BCLI, JAGX, and BLRXShould you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include COSCIENS Biopharma (CSCI), Relmada Therapeutics (RLMD), Calidi Biotherapeutics (CLDI), TherapeuticsMD (TXMD), Acurx Pharmaceuticals (ACXP), Apollomics (APLM), Cellectar Biosciences (CLRB), Brainstorm Cell Therapeutics (BCLI), Jaguar Health (JAGX), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical products" industry. InMed Pharmaceuticals vs. COSCIENS Biopharma Relmada Therapeutics Calidi Biotherapeutics TherapeuticsMD Acurx Pharmaceuticals Apollomics Cellectar Biosciences Brainstorm Cell Therapeutics Jaguar Health BioLineRx InMed Pharmaceuticals (NASDAQ:INM) and COSCIENS Biopharma (NASDAQ:CSCI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, community ranking, valuation, risk, media sentiment and analyst recommendations. Which has preferable valuation & earnings, INM or CSCI? InMed Pharmaceuticals has higher revenue and earnings than COSCIENS Biopharma. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than COSCIENS Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInMed Pharmaceuticals$4.60M0.83-$7.68M-$13.91-0.38COSCIENS Biopharma$4.50M2.49-$16.55M-$11.87-0.25 Do institutionals & insiders have more ownership in INM or CSCI? 20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 0.7% of COSCIENS Biopharma shares are held by institutional investors. 1.9% of InMed Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of COSCIENS Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to INM or CSCI? In the previous week, InMed Pharmaceuticals had 1 more articles in the media than COSCIENS Biopharma. MarketBeat recorded 1 mentions for InMed Pharmaceuticals and 0 mentions for COSCIENS Biopharma. InMed Pharmaceuticals' average media sentiment score of 1.00 beat COSCIENS Biopharma's score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment InMed Pharmaceuticals Positive COSCIENS Biopharma Neutral Which has more volatility & risk, INM or CSCI? InMed Pharmaceuticals has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, COSCIENS Biopharma has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Does the MarketBeat Community favor INM or CSCI? InMed Pharmaceuticals received 8 more outperform votes than COSCIENS Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformInMed PharmaceuticalsOutperform Votes847.06% Underperform Votes952.94% COSCIENS BiopharmaN/AN/A Is INM or CSCI more profitable? InMed Pharmaceuticals has a net margin of -137.41% compared to COSCIENS Biopharma's net margin of -428.43%. InMed Pharmaceuticals' return on equity of -65.74% beat COSCIENS Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets InMed Pharmaceuticals-137.41% -65.74% -53.57% COSCIENS Biopharma -428.43%-95.93%-45.66% SummaryInMed Pharmaceuticals beats COSCIENS Biopharma on 9 of the 14 factors compared between the two stocks. Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INM vs. The Competition Export to ExcelMetricInMed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.85M$6.53B$5.37B$9.10BDividend YieldN/A2.96%5.37%4.00%P/E Ratio-0.389.5287.4217.48Price / Sales0.83323.971,281.3978.80Price / CashN/A22.6336.6032.90Price / Book0.265.044.934.65Net Income-$7.68M$154.90M$117.96M$224.76M7 Day Performance29.19%2.05%2.21%2.97%1 Month Performance19.80%1.01%3.20%4.97%1 Year Performance-26.49%4.32%26.67%21.85% InMed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMInMed Pharmaceuticals1.1774 of 5 stars$5.05+2.0%N/A-31.0%$3.64M$4.60M-0.3610News CoveragePositive NewsGap UpTrading HaltedHigh Trading VolumeCSCICOSCIENS BiopharmaN/A$3.28-3.5%N/AN/A$12.33M$7.60M-0.2820Positive NewsRLMDRelmada Therapeutics4.0718 of 5 stars$0.40-3.0%$4.25+962.5%-89.1%$12.07MN/A-0.1410CLDICalidi Biotherapeutics3.0694 of 5 stars$0.92+0.3%$16.67+1,715.3%N/A$12.01M$50,000.000.0038TXMDTherapeuticsMD0.616 of 5 stars$1.04-5.5%N/A-52.5%$11.99M$1.60M0.00420ACXPAcurx Pharmaceuticals3.033 of 5 stars$0.70-13.0%$12.00+1,607.0%-76.1%$11.88MN/A-0.643Short Interest ↓APLMApollomics2.3923 of 5 stars$10.79+2.4%$200.00+1,753.6%-89.3%$11.73M$1.22M0.0045CLRBCellectar Biosciences2.8478 of 5 stars$0.28-0.6%$17.67+6,193.8%-93.0%$11.58MN/A-0.1610Analyst ForecastHigh Trading VolumeBCLIBrainstorm Cell Therapeutics4.5373 of 5 stars$2.00-1.0%$30.00+1,400.0%-55.1%$11.41MN/A-0.4240Analyst UpgradeNews CoverageGap UpJAGXJaguar Health0.5596 of 5 stars$0.93-6.8%N/A-86.1%$11.00M$10.48M0.0050BLRXBioLineRx2.9691 of 5 stars$0.14-4.8%$9.00+6,517.6%-92.5%$10.87M$21.99M-0.6240Analyst ForecastStock SplitNews CoverageGap Up Related Companies and Tools Related Companies CSCI Alternatives RLMD Alternatives CLDI Alternatives TXMD Alternatives ACXP Alternatives APLM Alternatives CLRB Alternatives BCLI Alternatives JAGX Alternatives BLRX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INM) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
